Table 1. Survival analysis for tamoxifen-treated patients using Cox regression model.

Variables used in the Cox regression model were dichotomized as shown in Supplementary Table 1. A) Higher BQ nuclear score was significantly associated with higher risk of death even after adjustment for clinical parameters including age, tumor grade, PR and HER2 status. (RR=2.117; p <0.001. B) Higher BQ nuclear score was significantly associated with higher risk of dying from cancer even after adjustment for clinical parameters including tumor grade, PR and HER2 status. (RR=2.604; p<0.001). #Cut off = 130 which is the median BQ nuclear score.

A. Cox regression analysis of overall survival predictors for patients with breast cancer

Clinical-pathological parameters	Univariate analysis		Multivariate analysis
	RR (95% Cl)	P value	RR (95% Cl)	P value
Age (n=358)	1.946 (1.36, 2.785)	0.000273	2.019 (1.359, 2.998)	0.001
T-stage (n=358)	1.123 (0.816, 1.546)	0.476
Lymph-node involvement	1.077 (0.472, 2.455)	0.861
Tumor-Grade	1.397 (1.035, 1.885)	0.029	1.634 (1.168, 2.286)	0.004
PR status	0.62 (0.448, 0.858)	0.004	0.792 (0.555, 1.13)	0.198
HER2 status	1.757 (1.136, 2.718)	0.011	1.888 (1.185, 3.008)	0.008
BQ nucleus score #	1.765 (1.317, 2.365)	<0.001	2.117 (1.520, 2.948)	<0.001

B. Cox regression analysis of disease-free survival predictors for patients with breast cancer
Clinical-pathological parameters	Univariate analysis		Multivariate analysis
	RR (95% Cl)	P value	RR (95% Cl)	P value
Age (n=358)	1.326 (0.887, 1.982)	0.169
T-stage (n=358)	1.326 (0.891, 1.973)	0.165
Lymph-node involvement	1.52 (0.495, 4.671)	0.465
Tumor-Grade	1.75 (1.197, 2.559)	0.004	1.997 (1.315, 3.033)	0.001
PR status	0.516 (0.352, 0.756)	0.001	0.58 (0.383, 0.878)	0.010
HER2 status	2.222 (1.377, 3.587)	0.001	1.906 (1.147, 3.169)	0.013
BQ nucleus score #	2.093 (1.459, 3.002)	<0.001	2.604 (1.746, 3.885)	<0.001